A management algorithm for congenital erythropoietic porphyria derived from a study of 29 cases
Open Access
- 16 July 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 167 (4), 888-900
- https://doi.org/10.1111/j.1365-2133.2012.11154.x
Abstract
Background Congenital erythropoietic porphyria (CEP) is an autosomal recessive photomutilating porphyria with onset usually in childhood, where haematological complications determine prognosis. Due to its extreme rarity and clinical heterogeneity, management decisions in CEP are often difficult. Objectives To develop a management algorithm for patients with CEP based on data from carefully characterized historical cases. Methods A single investigator collated data related to treatments and their outcomes in 29 patients with CEP from the U.K., France, Germany and Switzerland. Results Six children were treated with bone marrow transplantation (BMT); five have remained symptomatically cured up to 11·5 years post‐transplantation. Treatments such as oral charcoal, splenectomy and chronic hypertransfusion were either of no benefit or were associated with complications and negative impact on health‐related quality of life. Lack of consistent genotype–phenotype correlation meant that this could not be used to predict disease prognosis. The main poor prognostic factors were early age of disease onset and severity of haematological manifestations. Conclusions A management algorithm is proposed where every patient, irrespective of disease severity at presentation, should receive a comprehensive, multidisciplinary clinical assessment and should then be reviewed at intervals based on their predicted prognosis, and the rate of onset of complications. A BMT should be considered in those with progressive, symptomatic haemolytic anaemia and/or thrombocytopenia. Uroporphyrinogen III synthase genotypes associated with poor prognosis would additionally justify consideration for a BMT. Rigorous photoprotection of the skin and eyes from visible light is essential in all patients.Keywords
This publication has 33 references indexed in Scilit:
- Severe Neonatal Congenital Erythropoietic PorphyriaPediatric Dermatology, 2011
- Effective Gene Therapy of Mice with Congenital Erythropoietic Porphyria Is Facilitated by a Survival Advantage of Corrected Erythroid CellsAmerican Journal of Human Genetics, 2008
- The Family Dermatology Life Quality Index: measuring the secondary impact of skin diseaseBritish Journal of Dermatology, 2007
- Congenital erythropoietic porphyria due to a mutation in GATA1: the first trans-acting mutation causative for a human porphyriaBlood, 2006
- Successful match-unrelated donor bone marrow transplantation for congenital erythropoietic porphyria (Günther disease)European Journal of Pediatrics, 2004
- Treatment of congenital erythropoietic porphyria in children by allogeneic stem cell transplantation: a case report and review of the literatureBone Marrow Transplantation, 2001
- Congenital erythropoietic porphyriaJournal of the American Academy of Dermatology, 1997
- Correction of congenital erythropoietic porphyria by bone marrow transplantationThe Journal of Pediatrics, 1996
- Therapeutic Efficacy of Oral Charcoal in Congenital Erythropoietic PorphyriaThe New England Journal of Medicine, 1987
- Complete Suppression of the Symptoms of Congenital Erythropoietic Porphyria by Long-Term Treatment with High-Level TransfusionsThe New England Journal of Medicine, 1986